Elsevier

Drug Discovery Today

Volume 25, Issue 4, April 2020, Pages 668-688
Drug Discovery Today

Review
Keynote
Recent discovery and development of inhibitors targeting coronaviruses

https://doi.org/10.1016/j.drudis.2020.01.015Get rights and content

Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded RNA genome. Currently, six human CoVs have been reported including human coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus (MERS-CoV). They cause moderate to severe respiratory and intestinal infections in humans. In this review, we focus on recent advances in the research and development of small-molecule anti-human coronavirus therapies targeting different stages of the CoV life cycle.

Cited by (0)

Thanigaimalai Pillaiyar received his doctoral degree in medicinal chemistry in 2011 under the supervision of Prof. Dr Sang-Hun Jung at Chungnam National University, South Korea. In 2011, he won a ‘Japanese Society for the Promotion of Science Postdoctoral Fellowship (JSPS)’ for 2 years with Prof. Dr Yoshio Hayashi at Tokyo University of Pharmacy and Life Sciences, Japan. He was awarded an Alexander von Humboldt postdoctoral fellowship (AvH) in 2013 for 2 years with Prof. Dr Christa E. Müller at University of Bonn, Germany. Currently, he is working on developing modulators/inhibitors for various G-protein-coupled receptors.

Sangeetha Meenakshisundaram is working as Assistant Professor in the Department of Chemistry, Sri Krishna College of Engineering and Technology, Coimbatore, India. She pursued her Master of Science from Avinashilingam Deemed University and Master of Philosophy from Bharathiar University. In 2017, she obtained a PhD from Bharathiar University, Coimbatore, India. Her fields of interest include organic synthesis and medicinal chemistry.

Manoj Manickam received his PhD in 2010 from Bharathiar University, Coimbatore, India. He continued to work as a Research Associate at Orchid Chemicals and Pharmaceuticals. Then, he moved to Chungam National University, South Korea, to continue his research as a Postdoctoral Researcher and Research Professor working with Professor Sang-Hun Jung. Currently, he is working at the PSG Institute of Technology and Applied Research, Coimbatore, India, as Assistant Professor in the Department of Chemistry. He is actively involved in the preparation of small molecules for various therapeutic targets such as heart failure, hypertension and cancer.

View Abstract